ESC 2026: laroprovstat evaluated to close the LDL-C treatment gap

At ESC 2026 Scientific Sessions, preliminary Phase III data were presented from the ongoing AZURE-LDL trial evaluating laroprovstat. Laroprovstat could address persistent LDL-C treatment gaps, offering a new oral option for patients above recommended targets. Developed by AstraZeneca, laroprovstat provides another oral option for additional LDL-C reduction. Credit: Anna in Sweden via Shutterstock.com. Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth clinical trials industry analysis across drug development, clinical research, and trial innovation. With a free Clinical Trials Arena profile, you can: Experience unmatched clarity with a single platform that combines unique data, AI, and…

Source: Clinical Trials Arena